Skip to main content
. 2021 Jul 8;9:626657. doi: 10.3389/fped.2021.626657

Table 3.

The clinical characteristics in patients with DNM1L variants in different domains.

Clinical data GTPase domain Middle domain P-value
%(n/n)or n (n = 12) (n = 23)
Age of onset 0.5 (0.1–5) 0.5 (0.1–9) /
Sex Male 44.4% (4/9) 52.4% (11/21) 1.000
Female 55.6% (5/9) 47.6% (10/21)
The last Survive 83.3% (10/12) 56.5% (13/23) 0.149
follow-up death 16.7% (2/12) 43.5% (10/23)
Psychomotor retardation 50.0% (6/12) 91.3% (21/23) 0.011
Limb paralysis 66.7% (8/12) 64.3% (9/14) 1.000
     Dependent ambulation 2 2
     Stand 1
     Sitting 1
     No postural control 6 5
Dystonia 72.7% (8/11) 88.2% (15/17) 0.353
Epilepsy 8.3% (1/12) 89.5% (17/19) 0.000
     Status epilepticus 1 12
Ataxia 5 1 /
Nystagmus 1 1 /
Optic atrophy 4 1 /
Dysarthria 3 1 /
Microcephalus 1 3 /
Pain insensitivity 2 /
Sensory and motor axonal neuropathy 1 1 /
Abnormality in MR image 62.5% (5/8) 90.9% (20/22) 0.102
     Hyperintense in cortex 1 9 /
     Hyperintense in white matter 1 2 /
     Hyperintense in basal ganlia/ hypothalamus 4 6 /
     Cerebral atrophy 1 11 /
     thinning/absence of corpus callosum 0 3 /
     lactate peak 1 3 /
Abnormal EEG 20.0% (1/5) 92.9% (13/14) 0.006
     Epileptiform discharge 1 12
     Weak background 7
Hyperlactacidemia 57.1% (4/7) 65.0% (13/20) 0.661
decreased respiratory chain enzyme activity 0.0% (0/3) 36.4% (4/11) 0.505
Ragged red fibers 1 3 /
Abnormal morphology of mitochondria 5 6 /

Data are shown as prevalence %(n/n) or n(number). “–” indicates that it was not mentioned in the literature. Statistical analysis included the chi-square test or Fisher's exact probability, as appropriate. “/” indicates that no statistical analysis was performed.